finance

U.S. FDA considering lowering recommended age for Pfizer/BioNTech COVID-19 boosters



© Reuters. FILE PHOTO: A nurses fills up syringes for patients as they receive their coronavirus disease (COVID-19) booster vaccination during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, U.S., September 29, 2021. REUTERS/Emily Elconin

NEW YORK (Reuters) – A top U.S. Food and Drug Administration official said on Friday that the agency is considering lowering the recommended age for who should receive booster shots of the Pfizer/BioNTech COVID-19 vaccine to as young as 40 years old, based on data from Israel suggesting the vaccine’s efficacy is waning.

Israeli scientists presented “data that seemed compelling in the 40 and up age range,” Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research said, speaking to the agency’s Vaccines and Related Biological Products Advisory Committee.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Read More   Stocks making the biggest moves midday: Wynn, SoFi, Diamondback Energy and more





READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.